Lexeo Therapeutics Announces Complete Enrollment of LX2006 SUNRISE-FA Phase 1/2 trial and Alignment with FDA on an Accelerated Approval Pathway
Industry News
News|Nov 14 2024
Larimar Therapeutics Announces Three Poster Presentations at the 2024 International Congress for Ataxia Research (ICAR) on November 12–15, 2024
Industry News
News|Nov 12 2024
Capsida Biotherapeutics to Present New Preclinical Data for Friedreich’s Ataxia Next-Generation Gene Therapy to Target CNS, Cardiac Tissues and Sensory Regions
Industry News
News|Nov 12 2024
Global Ataxia Advocacy Organizations Unite to Host Largest International Congress for Ataxia Research in London
FARA News | Research
News|Oct 16 2024
Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia
Industry News
News|Oct 8 2024
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
Industry News
News|Sep 20 2024
Congressional Resolution Passes to Designate September 25 as “National Ataxia Awareness Day”
Advocacy
News|Sep 17 2024
Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia
Industry News
News|Sep 11 2024
Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance and FARA Ireland to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia
FARA News | Industry News | Research
News|Sep 10 2024
Meet the 2024 FARA Fellows
FARA News | Research
News|Sep 4 2024
FA Community Conversations Genetic Therapies Webinar: Recording Available on YouTube
Education
News|Aug 27 2024
FARA Celebrates 16 Years of Funding Adaptive Cycling Equipment Through The Ataxian Athlete Initiative (AAI)